Novo · Grow Your Brand · A century of diabetes science under pressure to widen access · Denmark / Active
Novo
Novo shortens the name. The proof still rests on medicines and access. Novo Nordisk adopted Novo as its everyday name on 14 September 2026. The shorter name and right-facing Apis connect a familiar scientific history with a more consumer-facing identity. Medicine access and pipeline delivery still have to make the promise credible.
Positioning, name, and architecture.
Three evidence checks before the page talks about scale, color, or public reaction.
Deep metabolic-science leadership connected to large-scale injectable and oral medicine production.
Novo Nordisk translates metabolic science into medicines whose brand promise is tested by evidence, supply and affordability.
The 1989 merger joined Novo and Nordisk. Since 14 September 2026, Novo is the everyday brand; Novo Nordisk A/S remains the legal company name.
Lasting Health Starts Now
branded corporate parent / product-brand portfolio
Novo is the day-to-day parent brand; Novo Nordisk A/S is the legal entity. Ozempic, Wegovy and the other medicine names retain their product roles.
Insulin and GLP-1 medicines for diabetes.
therapeutic area: Ozempic and Rybelsus source
Prescription medicines for chronic weight management.
therapeutic area: Wegovy source
Haemophilia, growth and endocrine therapies.
therapeutic area: Rare-disease portfolio source
CagriSema combines cagrilintide and semaglutide; clinical results are separate from approval.
development portfolio: CagriSema source
Naming and tagline progression
Nordisk insulin heritage begins.
Novo Nordisk joins two company names.
Driving change to defeat serious chronic diseases.
Lasting Health Starts Now
Market and scale snapshot.
Q2 2026 results use Novo Nordisk's reported Danish kroner, with machine-readable USD fields translated at the 10 Aug 2026 DKK/USD reference rate. Raised guidance did not remove pressure around Wegovy pill demand, access, and the future portfolio.
DKK 78.5B in Q2 2026 adjusted sales, up 7% at constant exchange rates. USD translation uses the existing 10 Aug 2026 reference rate.
DKK 33.389B in Q2 2026 adjusted operating profit, up 11% at constant exchange rates. USD translation uses the existing 10 Aug 2026 reference rate.
Approximate equity market capitalization observed 10 Aug 2026.
Copenhagen and NYSE listings; Novo Nordisk A/S.
Color system.
Lasting Blue replaces True Blue, with Now Turquoise as the accent and a new typeface named Novo. Swatches are sampled from official launch assets, not print specifications.
How the palette behaves
The brighter blue keeps continuity with the old identity while changing its appearance.
Turquoise is the accent, rather than a replacement for the blue parent brand.
Novo is the new corporate typeface. Product names continue to do separate recognition work.
Recognition assets.
Memory pieces the brand can use before someone finishes a sentence.
The 2026 Apis turns right but keeps the bull and sun-disc recognition cues.
The new palette separates the refreshed parent from its previous True Blue system.
For high-demand medicines, production and access become visible brand evidence.
Scores.
Use these scores to compare recognition, trust, proof, pressure, and risk.
Product names and Apis symbol are globally visible.
Therapeutic areas and product brands have clear roles.
Clinical evidence is the core demand engine.
Patient purpose softens a technical parent identity.
Access and pricing pressure can erode goodwill.
Parent, therapies and products can be separated cleanly.
Apis and blue create stable continuity.
Global demand makes supply and affordability visible.
How the logo changed.
The Apis survives the name change. The 2026 version changes direction, silhouette and wordmark; the earlier marks remain part of the same company history.
The first merged Novo Nordisk masterbrand used a black Apis bull and sun disc after the 1989 combination. source
A blue, dimensional Apis and lowercase name modernized the post-merger corporate identity. source
The outline Apis appears in the 2010s on Novo’s official history chart. It preceded the September 2026 refresh. source
The bull turns right beside the shortened Novo name. This is the official corporate lockup, not a product mark. source
Product and service lineage.
The strongest growth moves build on the same scientific capability while expanding the people and conditions the company serves.
Format evolution
The visual is conceptual, not documentary: the brand keeps translating biological science into treatment formats people can use.
Device lineage
NovoPen made insulin delivery more discreet and accurate, turning industrial design into part of the care experience.
Wegovy pill production
The oral obesity launch turns supply reliability into visible brand evidence as demand grows.
Production inheritance
Manufacturing scale has carried the brand promise for decades; capacity and access remain linked today.
Product and service system
Nordisk begins commercial insulin production.
Novo and Nordisk merge.
Liraglutide launches for diabetes.
Semaglutide launches as Ozempic.
Wegovy launches for chronic weight management.
Access, oral formats and new indications widen the debate.
CagriSema adds an amylin-and-GLP-1 combination to the portfolio in development.
Turning points.
The September identity launch sits beside a harder test: a new pipeline must replace growth that investors no longer take for granted.
Sales reach DKK 309.06B and net profit DKK 102.43B.
Novo Nordisk guides to a sales and operating-profit decline at constant exchange rates.
New lower-cost semaglutide access and expanded Wegovy approvals keep the company in daily discussion.
Adjusted operating profit rose 11% to DKK 33.389B and guidance increased, while Wegovy pill demand, access, and future portfolio expectations kept pressure on the story.
Novo replaces Novo Nordisk in everyday branding. The legal company name stays Novo Nordisk A/S.
The Novo Way sets out customer focus, competitiveness, clarity, and care and integrity.
Novo targets more than five multi-blockbuster launches by 2030 and over DKK 150B in risk-adjusted pipeline sales in 2035.
Novo reported estimated 60-week weight loss of 12.4% with investigational CagriSema 1.0 mg/1.0 mg versus 9.1% with tirzepatide 5 mg, using the efficacy estimand. REIMAGINE 5 enrolled adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both.
Reuters reported 13,000 staff departures: 9,000 initial layoffs and 4,000 later exits. Shares were down just under 4.4% at 12:46 GMT after deeper early losses.
Public reaction.
Breakthrough demand and access frustration can be true at the same time.
Semaglutide moved obesity and diabetes treatment into mainstream discussion.
Price, coverage, compounding and supply tensions test whether the promise reaches enough people.
Reuters described investor scrutiny of pricing assumptions and semaglutide patent expiry at the capital-markets presentation.
Full timeline.
Nordisk Insulinlaboratorium is founded.
Novo Terapeutisk Laboratorium begins insulin production.
Novo and Nordisk merge.
The Novo group introduces refreshed brand identities.
Ozempic is approved in the United States.
Wegovy is approved for chronic weight management.
Adjusted operating profit reaches DKK 33.389B as Novo raises guidance and the Wegovy pill passes 5 million U.S. prescriptions.
Novo replaces Novo Nordisk in everyday branding. The legal company name stays Novo Nordisk A/S.
Novo targets more than five multi-blockbuster launches by 2030 and over DKK 150B in risk-adjusted pipeline sales in 2035.
Novo reported estimated 60-week weight loss of 12.4% with investigational CagriSema 1.0 mg/1.0 mg versus 9.1% with tirzepatide 5 mg, using the efficacy estimand. REIMAGINE 5 enrolled adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both.
Reuters reported 13,000 staff departures: 9,000 initial layoffs and 4,000 later exits. Shares were down just under 4.4% at 12:46 GMT after deeper early losses.
Steal / avoid.
- Let a durable corporate symbol carry continuity across scientific change.
- Keep therapeutic areas and product brands in explicit roles.
- Treat manufacturing and access as brand proof when demand is high.
- Do not let product hype outrun access reality.
- Do not blur clinical evidence with lifestyle aspiration.
- Do not hide category pressure behind a century-old purpose.
Short answer.
Novo is the everyday brand name adopted by Novo Nordisk on 14 September 2026. Novo Nordisk A/S remains the legal company. The updated Apis, Lasting Blue, Now Turquoise and Novo typeface accompany the platform Lasting Health Starts Now.
Frequently asked questions
What is Novo Nordisk's core brand signal?
A century of metabolic science translated into recognizable medicines and a global access system.
What should another brand steal from Novo Nordisk?
Use a stable corporate symbol and purpose while product brands do specific demand work.
What is the current pressure point?
Affordability, supply and stronger GLP-1 competition.
What was Novo Nordisk's 2025 Global 500 rank?
Novo Nordisk ranked number 368 in the 2025 Fortune Global 500.
Did Novo Nordisk change its legal name?
No. Novo became the everyday brand on 14 September 2026; Novo Nordisk A/S remains the legal global company name.
What changed in the Novo logo and identity?
The Apis now faces right beside Novo. Lasting Blue, Now Turquoise, the Novo typeface and Lasting Health Starts Now form the updated system.
Did the CagriSema trial prove superiority at every dose?
No. The reported REIMAGINE 5 comparison used the efficacy estimand at 60 weeks: CagriSema 1.0 mg/1.0 mg against tirzepatide 5 mg in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both. CagriSema remained investigational.
Need help with your own brand?
Use Private brand work when your name, identity, proof, or message needs a sharper branding decision.
Sources.
Use the education shelf for the concepts behind this brand page.
Private brand workUse this when the decision belongs to your own brand.
All brandsReturn to every brand page.
- Annual Report 2025
- FY2025 financial performance
- ECB 2025 annual DKK/EUR average
- ECB 2025 annual USD/EUR average
- Q1 2026 investor presentation
- Novo Nordisk Q2 2026 financial results
- Novo Nordisk market capitalization
- DKK to USD reference rate, 10 Aug 2026
- Official heritage
- Official logo evolution
- Official design manual
- Lower-cost Ozempic access, 17 Jul 2026
- Wegovy approval, 17 Jul 2026
- Novo rebrand announcement, 14 September 2026
- Official Novo identity and downloadable logos
- Novo Capital Markets Day ambitions, 21 September 2026
- Novo REIMAGINE 5 topline trial results
- Reuters: capital-markets reaction and workforce departures